An incredible 17,000 volunteers recruited in just 17 months!

Posted:
20
October 2003

Richmond Pharmacology has an exceptional volunteer database of over 17,000 volunteers and continues to outshine the competition, recruiting on average 1,000 new volunteers each month.

Richmond has far surpassed other CROs, which take many years to build a similarly substantial database of potential volunteers. Richmonds unparalleled and proactive recruitment strategy has taken just 17 months to achieve an outstanding 17,000 volunteers on the database.Richmonds huge success with volunteer recruitment speaks for itself, having started eight new studies on time, during August this year, which included a record 158 volunteers! This demonstrates the efficiency of Richmonds process and the dedication of its staff.The substantial database also holds a wide range of patient populations which ensures that Richmonds first-rate recruitment team continue to meet all recruitment targets – particularly those for special populations – while offering a standard of service unmatched by competitors – providing clients with an efficient, superior trial with quality driven results.Richmond Pharmacology has – according to third parties – by far the largest dedicated volunteer recruitment department of any Phase 1 CRO in the UK, meaning delivery of volunteer numbers is guaranteed within the quoted budget, at no extra cost to the clients.Richmond Pharmacology’s recruitment website, www.trials4us.co.uk is designed for volunteers and includes specific information, frequently asked questions and online registration.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more